JP2019521668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521668A5 JP2019521668A5 JP2018563156A JP2018563156A JP2019521668A5 JP 2019521668 A5 JP2019521668 A5 JP 2019521668A5 JP 2018563156 A JP2018563156 A JP 2018563156A JP 2018563156 A JP2018563156 A JP 2018563156A JP 2019521668 A5 JP2019521668 A5 JP 2019521668A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- human
- light chain
- human animal
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 claims description 47
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 claims description 47
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 45
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 38
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 33
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 28
- 150000007523 nucleic acids Chemical group 0.000 claims description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 25
- 108060003951 Immunoglobulin Proteins 0.000 claims description 21
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 21
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 21
- 102000018358 immunoglobulin Human genes 0.000 claims description 21
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 18
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 17
- 241000894007 species Species 0.000 claims description 12
- 101001061851 Homo sapiens V(D)J recombination-activating protein 2 Proteins 0.000 claims description 10
- 102000001183 RAG-1 Human genes 0.000 claims description 10
- 108060006897 RAG1 Proteins 0.000 claims description 10
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 claims description 10
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 claims description 9
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 claims description 9
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 8
- 210000001948 pro-b lymphocyte Anatomy 0.000 claims description 8
- 210000004602 germ cell Anatomy 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 241000283984 Rodentia Species 0.000 claims description 5
- 108010029485 Protein Isoforms Proteins 0.000 claims description 4
- 102000001708 Protein Isoforms Human genes 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000011712 cell development Effects 0.000 claims description 3
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 claims 17
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 claims 17
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 claims 15
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 claims 15
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 15
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 claims 15
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 6
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 6
- 102100029572 Immunoglobulin kappa constant Human genes 0.000 claims 6
- 101710139965 Immunoglobulin kappa constant Proteins 0.000 claims 6
- 101000800646 Homo sapiens DNA nucleotidylexotransferase Proteins 0.000 claims 5
- 101150097493 D gene Proteins 0.000 claims 3
- 108700029228 Immunoglobulin Heavy Chain Genes Proteins 0.000 claims 3
- 101150008942 J gene Proteins 0.000 claims 3
- 210000001161 mammalian embryo Anatomy 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 24
- 108091008874 T cell receptors Proteins 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108700026220 vif Genes Proteins 0.000 description 6
- 238000012239 gene modification Methods 0.000 description 5
- 230000005017 genetic modification Effects 0.000 description 5
- 235000013617 genetically modified food Nutrition 0.000 description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022058938A JP7274018B2 (ja) | 2016-06-03 | 2022-03-31 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345524P | 2016-06-03 | 2016-06-03 | |
| US62/345,524 | 2016-06-03 | ||
| PCT/US2017/035731 WO2017210586A1 (en) | 2016-06-03 | 2017-06-02 | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022058938A Division JP7274018B2 (ja) | 2016-06-03 | 2022-03-31 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521668A JP2019521668A (ja) | 2019-08-08 |
| JP2019521668A5 true JP2019521668A5 (cg-RX-API-DMAC7.html) | 2020-07-09 |
| JP7053499B2 JP7053499B2 (ja) | 2022-04-12 |
Family
ID=59215996
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563156A Active JP7053499B2 (ja) | 2016-06-03 | 2017-06-02 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| JP2022058938A Active JP7274018B2 (ja) | 2016-06-03 | 2022-03-31 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| JP2023074624A Active JP7586960B2 (ja) | 2016-06-03 | 2023-04-28 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| JP2024195337A Pending JP2025020339A (ja) | 2016-06-03 | 2024-11-07 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022058938A Active JP7274018B2 (ja) | 2016-06-03 | 2022-03-31 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| JP2023074624A Active JP7586960B2 (ja) | 2016-06-03 | 2023-04-28 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
| JP2024195337A Pending JP2025020339A (ja) | 2016-06-03 | 2024-11-07 | 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 |
Country Status (25)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| EP3462853B1 (en) | 2016-06-03 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Rodents expressing exogenous terminal deoxynucleotidyltransferase |
| PT3720279T (pt) | 2017-12-05 | 2022-10-06 | Regeneron Pharma | Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos |
| HUE070158T2 (hu) * | 2018-03-24 | 2025-05-28 | Regeneron Pharma | Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk |
| CA3102795A1 (en) * | 2018-06-13 | 2019-12-19 | The Children's Medical Center Corporation | Methods and compositions relating to high-throughput models for antibody discovery and/or optimization |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| AU2020226865A1 (en) * | 2019-02-22 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Rodents having genetically modified sodium channels and methods of use thereof |
| CA3136478A1 (en) | 2019-06-05 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
| IL293820A (en) * | 2019-12-12 | 2022-08-01 | Dna Script | Chimeric-terminal deoxynucleotidyltransferases for template-independent enzymatic synthesis of polynucleotides |
| CN111057754B (zh) * | 2019-12-27 | 2021-01-12 | 四川省医学科学院.四川省人民医院实验动物研究所 | 鉴定适用于hbv研究的动物模型的方法和应用 |
| US12250931B2 (en) | 2020-01-28 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with a humanized PNPLA3 gene and methods of use |
| EP4138550A1 (en) * | 2020-04-21 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cxcl13 gene |
| IL301137A (en) | 2020-09-11 | 2023-05-01 | Regeneron Pharma | Identification and production of antigen-specific antibodies |
| CN116848254A (zh) | 2020-12-16 | 2023-10-03 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
| EP4559939A3 (en) | 2020-12-23 | 2025-09-24 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses therof |
| AU2022249328A1 (en) * | 2021-03-31 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire |
| KR20250077529A (ko) * | 2022-09-22 | 2025-05-30 | 리제너론 파아마슈티컬스, 인크. | 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스 |
| NL2037811B1 (en) | 2024-05-29 | 2025-12-12 | Univ Oslo | Treatment for Cancer |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9119338D0 (en) | 1991-09-10 | 1991-10-23 | Inst Of Animal Physiology And | Control of gene expression |
| US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| US5512295A (en) | 1994-11-10 | 1996-04-30 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic liposomes for enhanced uptake and delivery |
| US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6770291B2 (en) | 1996-08-30 | 2004-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US7001614B2 (en) | 1996-08-19 | 2006-02-21 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US7112338B2 (en) | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6749863B1 (en) | 1997-11-19 | 2004-06-15 | Georgetown University | Targeted liposome gene delivery |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP2294917A1 (en) | 2001-03-22 | 2011-03-16 | Abbott GmbH & Co. KG | Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20090042291A1 (en) | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA2510309C (en) | 2002-12-16 | 2014-09-16 | Liyange P. Perera | Recombinant vaccine viruses expressing il-15 and methods of using the same |
| CA2514517A1 (en) | 2003-01-28 | 2004-08-12 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| US8218805B2 (en) | 2003-10-11 | 2012-07-10 | Charles Hornback | Wireless speaker system for use with ceiling fans |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| WO2005116072A2 (en) | 2004-05-27 | 2005-12-08 | Weidanz Jon A | Antibodies as t cell receptor mimics, methods of production and uses thereof |
| PL1802193T3 (pl) | 2004-10-19 | 2014-09-30 | Regeneron Pharma | Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| US20060222653A1 (en) | 2004-11-12 | 2006-10-05 | Xencor, Inc. | Antibodies operably linked to selected chemoattractants |
| EP1858925A2 (en) | 2005-01-12 | 2007-11-28 | Xencor, Inc. | Antibodies and fc fusion proteins with altered immunogenicity |
| JP5188969B2 (ja) * | 2005-08-03 | 2013-04-24 | セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド | ヒト化免疫グロブリンを発現するトランスジェニック動物におけるｂ細胞アポトーシスの抑制 |
| EP1928495A2 (en) | 2005-08-19 | 2008-06-11 | Cerus Corporation | Antibody-mediated enhancement of immune response |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| EP2003960B1 (en) | 2006-03-31 | 2015-06-10 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| SI2602323T1 (en) | 2007-06-01 | 2018-05-31 | Open Monoclonal Technology, Inc. | Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies |
| NZ584042A (en) | 2007-10-18 | 2012-09-28 | Bn Immunotherapeutics Inc | Use of mva to treat prostate cancer |
| US8225343B2 (en) | 2008-01-11 | 2012-07-17 | Sony Computer Entertainment America Llc | Gesture cataloging and recognition |
| DK2556747T3 (da) * | 2008-06-27 | 2021-02-15 | Merus Nv | Antistofproducerende transgen mus |
| DK2346994T3 (da) | 2008-09-30 | 2022-02-28 | Ablexis Llc | Knock-in-mus til fremstilling af kimære antistoffer |
| US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
| EP2517556B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| DK2509409T3 (en) | 2009-12-10 | 2016-11-14 | Regeneron Pharma | MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| WO2011097603A1 (en) | 2010-02-08 | 2011-08-11 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| AU2011235569B2 (en) | 2010-03-29 | 2016-06-30 | Zymeworks Bc Inc. | Antibodies with enhanced or suppressed effector function |
| KR102004106B1 (ko) | 2010-03-31 | 2019-07-25 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작 |
| SMT201900241T1 (it) | 2010-06-22 | 2019-05-10 | Regeneron Pharma | Topi esprimenti una catena leggera ibrida di immunoglobulina con una regione variabile umana |
| DK2597945T3 (da) | 2010-07-26 | 2020-09-21 | Trianni Inc | Transgene dyr og fremgangsmåder til anvendelse deraf |
| RS55495B1 (sr) | 2010-08-02 | 2017-04-28 | Regeneron Pharma | Miševi koji stvaraju vezujuće proteine koji sadrže vl domene |
| HRP20230526T1 (hr) | 2011-02-25 | 2023-09-01 | Regeneron Pharmaceuticals, Inc. | Adam6 miševi |
| JP5893258B2 (ja) | 2011-03-31 | 2016-03-23 | フェリカネットワークス株式会社 | 情報処理装置および方法、並びにプログラム |
| US20130018582A1 (en) | 2011-07-13 | 2013-01-17 | Miller Paul A | Inertial Navigation Common Azimuth Reference Determination System and Method |
| SI3865581T1 (sl) | 2011-08-05 | 2024-12-31 | Regeneron Pharmaceuticals, Inc. | Miši s humanizirano univerzalno lahko verigo |
| CA2846319A1 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| SG10202010120XA (en) | 2011-10-17 | 2020-11-27 | Regeneron Pharma | Restricted immunoglobulin heavy chain mice |
| LT3590332T (lt) | 2011-10-28 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules |
| WO2013063556A1 (en) | 2011-10-28 | 2013-05-02 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
| IN2014CN03890A (cg-RX-API-DMAC7.html) | 2011-10-28 | 2015-10-16 | Regeneron Pharma | |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| LT3262932T (lt) | 2011-10-28 | 2019-08-26 | Regeneron Pharmaceuticals, Inc. | Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu |
| US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| KR102052774B1 (ko) | 2011-11-04 | 2019-12-04 | 자임워크스 인코포레이티드 | Ｆｃ 도메인 내의 돌연변이를 갖는 안정한 이종이합체 항체 설계 |
| US9120662B2 (en) | 2011-11-14 | 2015-09-01 | Susan A. Thomson | Gathering and dispensing scoop with gate valve |
| US9547499B2 (en) | 2011-12-09 | 2017-01-17 | Microsoft Technology Licensing, Llc | Device configuration with cached pre-assembled driver state |
| RU2644684C2 (ru) | 2012-03-16 | 2018-02-13 | Регенерон Фармасьютикалз, Инк. | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения |
| AU2013204581B2 (en) * | 2012-03-16 | 2015-06-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
| HUE045537T2 (hu) | 2012-03-16 | 2019-12-30 | Regeneron Pharma | PH-érzékeny immunglobulin-szekvenciákat expresszáló rágcsálók |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| JP5920830B2 (ja) | 2012-09-28 | 2016-05-18 | シスメックス株式会社 | 試料調製装置および細胞分析装置 |
| ES2963516T3 (es) | 2012-12-14 | 2024-03-27 | Omniab Inc | Polinucleótidos que codifican anticuerpos de roedores con idiotipos humanos y animales que los contienen |
| SMT201900429T1 (it) | 2013-02-20 | 2019-09-09 | Regeneron Pharma | Topi esprimenti co-recettori umanizzati linfociti t |
| WO2014130690A1 (en) * | 2013-02-20 | 2014-08-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
| EP2958937B1 (en) | 2013-02-22 | 2018-08-15 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized major histocompatibility complex |
| HUE040575T2 (hu) | 2013-04-16 | 2019-03-28 | Regeneron Pharma | A patkány genom célzott módosítása |
| US9783618B2 (en) * | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9546384B2 (en) | 2013-12-11 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a mouse genome |
| WO2015143406A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| ES2872475T3 (es) | 2014-03-21 | 2021-11-02 | Regeneron Pharma | Animales no humanos que producen proteínas de unión de dominio único |
| LT3152312T (lt) | 2014-06-06 | 2020-04-27 | Regeneron Pharmaceuticals, Inc. | Tikslinio lokuso modifikavimo būdai ir kompozicijos |
| WO2015196051A1 (en) * | 2014-06-19 | 2015-12-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized programmed cell death 1 gene |
| JP6336140B2 (ja) | 2014-06-23 | 2018-06-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ヌクレアーゼ媒介ｄｎａアセンブリ |
| EP3461885B1 (en) | 2014-06-26 | 2021-10-20 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
| JP2017529841A (ja) * | 2014-09-19 | 2017-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | キメラ抗原受容体 |
| DK3280257T3 (da) | 2015-04-06 | 2023-09-04 | Regeneron Pharma | Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr |
| EP3462853B1 (en) | 2016-06-03 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Rodents expressing exogenous terminal deoxynucleotidyltransferase |
-
2017
- 2017-06-02 EP EP17733223.6A patent/EP3462853B1/en active Active
- 2017-06-02 JP JP2018563156A patent/JP7053499B2/ja active Active
- 2017-06-02 SM SM20250152T patent/SMT202500152T1/it unknown
- 2017-06-02 ES ES17733223T patent/ES2941810T3/es active Active
- 2017-06-02 CN CN201780048900.5A patent/CN109640644B/zh active Active
- 2017-06-02 SG SG10201914014XA patent/SG10201914014XA/en unknown
- 2017-06-02 HR HRP20230497TT patent/HRP20230497T1/hr unknown
- 2017-06-02 HU HUE23151094A patent/HUE071052T2/hu unknown
- 2017-06-02 BR BR112018074794-7A patent/BR112018074794A2/pt unknown
- 2017-06-02 CN CN202111170801.9A patent/CN113907043B/zh active Active
- 2017-06-02 SG SG11201810757YA patent/SG11201810757YA/en unknown
- 2017-06-02 WO PCT/US2017/035731 patent/WO2017210586A1/en not_active Ceased
- 2017-06-02 SM SM20230132T patent/SMT202300132T1/it unknown
- 2017-06-02 MX MX2018014982A patent/MX385681B/es unknown
- 2017-06-02 US US15/612,625 patent/US10980221B2/en active Active
- 2017-06-02 RU RU2018144954A patent/RU2753585C2/ru active
- 2017-06-02 KR KR1020187036917A patent/KR102483193B1/ko active Active
- 2017-06-02 KR KR1020227045806A patent/KR102598120B1/ko active Active
- 2017-06-02 RS RS20250364A patent/RS66700B1/sr unknown
- 2017-06-02 EP EP23151094.2A patent/EP4218408B1/en active Active
- 2017-06-02 LT LTEP23151094.2T patent/LT4218408T/lt unknown
- 2017-06-02 CN CN202310402666.9A patent/CN116458475A/zh active Pending
- 2017-06-02 PL PL17733223.6T patent/PL3462853T3/pl unknown
- 2017-06-02 SI SI201731599T patent/SI4218408T1/sl unknown
- 2017-06-02 PL PL23151094.2T patent/PL4218408T3/pl unknown
- 2017-06-02 HR HRP20250471TT patent/HRP20250471T1/hr unknown
- 2017-06-02 LT LTEPPCT/US2017/035731T patent/LT3462853T/lt unknown
- 2017-06-02 IL IL263160A patent/IL263160B2/en unknown
- 2017-06-02 DK DK17733223.6T patent/DK3462853T3/da active
- 2017-06-02 EP EP25156585.9A patent/EP4567104A3/en active Pending
- 2017-06-02 PT PT177332236T patent/PT3462853T/pt unknown
- 2017-06-02 RS RS20230395A patent/RS64216B1/sr unknown
- 2017-06-02 HU HUE17733223A patent/HUE061619T2/hu unknown
- 2017-06-02 FI FIEP23151094.2T patent/FI4218408T3/fi active
- 2017-06-02 PT PT231510942T patent/PT4218408T/pt unknown
- 2017-06-02 AU AU2017272337A patent/AU2017272337C1/en active Active
- 2017-06-02 SI SI201731323T patent/SI3462853T1/sl unknown
- 2017-06-02 KR KR1020237037578A patent/KR102784608B1/ko active Active
- 2017-06-02 CA CA3026088A patent/CA3026088A1/en active Pending
- 2017-06-02 FI FIEP17733223.6T patent/FI3462853T3/fi active
- 2017-06-02 DK DK23151094.2T patent/DK4218408T3/da active
- 2017-06-02 ES ES23151094T patent/ES3018427T3/es active Active
-
2018
- 2018-11-30 MX MX2021010351A patent/MX2021010351A/es unknown
- 2018-11-30 MX MX2021010352A patent/MX2021010352A/es unknown
-
2021
- 2021-03-16 US US17/203,398 patent/US12295354B2/en active Active
-
2022
- 2022-03-31 JP JP2022058938A patent/JP7274018B2/ja active Active
-
2023
- 2023-04-28 JP JP2023074624A patent/JP7586960B2/ja active Active
- 2023-05-31 CY CY20231100257T patent/CY1126063T1/el unknown
- 2023-07-30 IL IL304839A patent/IL304839A/en unknown
-
2024
- 2024-01-31 AU AU2024200577A patent/AU2024200577A1/en active Pending
- 2024-11-07 JP JP2024195337A patent/JP2025020339A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521668A5 (cg-RX-API-DMAC7.html) | ||
| RU2018144954A (ru) | Животные, не являющиеся человеком, экспрессирующие экзогенную терминальную дезоксинуклеотидилтрансферазу | |
| EP2792236B2 (en) | Animal models and therapeutic molecules | |
| JP2021505141A5 (cg-RX-API-DMAC7.html) | ||
| GB2495083A (en) | Human VpreB and chimaeric surrogate light chains in transgenic non-human vertebrates | |
| HK40058708B (en) | Rodent models and therapeutic molecules | |
| HK40060958B (en) | Rodent models and therapeutic molecules | |
| HK40058708A (en) | Rodent models and therapeutic molecules | |
| NZ749707B2 (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| HK40014992B (en) | Animal models and therapeutic molecules | |
| HK40014992A (en) | Animal models and therapeutic molecules | |
| HK40014986B (en) | Animal models and therapeutic molecules | |
| HK40014986A (en) | Animal models and therapeutic molecules | |
| HK1202373B (en) | Animal models and therapeutic molecules | |
| HK1184965A (en) | Animal models and therapeutic molecules | |
| HK1180535B (en) | Animal models and therapeutic molecules | |
| HK1184966A (en) | Animal models and therapeutic molecules |